Protein Abundance of Hepatic Drug Transporters in Patients With Different Forms of Liver Damage

2019 ◽  
Vol 107 (5) ◽  
pp. 1138-1148 ◽  
Author(s):  
Marek Drozdzik ◽  
Sylwia Szelag‐Pieniek ◽  
Mariola Post ◽  
Samir Zeair ◽  
Maciej Wrzesinski ◽  
...  
Keyword(s):  
Liver Damage ◽  
Drug Transporters ◽  
Protein Abundance ◽  
Hepatic Drug

scholarly journals Endotoxin-Mediated Downregulation of Hepatic Drug Transporters in HIV-1 Transgenic Rats

2016 ◽  
Vol 44 (5) ◽  
pp. 709-719 ◽  
Author(s):  
R. H. Ghoneim ◽  
M. Piquette-Miller
Keyword(s):  
Drug Transporters ◽  
Transgenic Rats ◽  
Hepatic Drug ◽  
Hiv 1

scholarly journals Comparison of Proteomic Quantification Approaches for Hepatic Drug Transporters: Multiplexed Global Quantitation Correlates with Targeted Proteomic Quantitation

2018 ◽  
Vol 46 (5) ◽  
pp. 692-696 ◽  
Author(s):  
Anna Vildhede ◽  
Chuong Nguyen ◽  
Brian K. Erickson ◽  
Ryan C. Kunz ◽  
Richard Jones ◽  
...  
Keyword(s):  
Drug Transporters ◽  
Hepatic Drug

scholarly journals Ontogeny of Hepatic Drug Transporters as Quantified by LC-MS/MS Proteomics

2016 ◽  
Vol 100 (4) ◽  
pp. 362-370 ◽  
Author(s):  
B Prasad ◽  
A Gaedigk ◽  
M Vrana ◽  
R Gaedigk ◽  
JS Leeder ◽  
...  
Keyword(s):  
Drug Transporters ◽  
Hepatic Drug

Circadian expression of hepatic drug transporters and their role in the hepatic excretion of phenolsulfonphthalein

2018 ◽  
Vol 33 (1) ◽  
pp. S94-S95
Author(s):  
Ju-Hee Oh ◽  
Miri Kim ◽  
Joo Hyun Lee ◽  
Sehyung Cho ◽  
Dong-Hee Han ◽  
...  
Keyword(s):  
Drug Transporters ◽  
Hepatic Drug ◽  
Circadian Expression

Primary hepatocyte cultures as prominentin vitrotools to study hepatic drug transporters

2013 ◽  
Vol 45 (2) ◽  
pp. 196-217 ◽  
Author(s):  
Eva Ramboer ◽  
Tamara Vanhaecke ◽  
Vera Rogiers ◽  
Mathieu Vinken
Keyword(s):  
Drug Transporters ◽  
Primary Hepatocyte ◽  
Hepatic Drug ◽  
Hepatocyte Cultures ◽  
Primary Hepatocyte Cultures

Hepatitis C Virus-related Cirrhosis is a Major Determinant of the Expression Levels of Hepatic Drug Transporters

2010 ◽  
Vol 25 (2) ◽  
pp. 190-199 ◽  
Author(s):  
Ken Ogasawara ◽  
Tomohiro Terada ◽  
Toshiya Katsura ◽  
Etsuro Hatano ◽  
Iwao Ikai ◽  
...  
Keyword(s):  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Drug Transporters ◽  
Major Determinant ◽  
Hepatic Drug ◽  
Expression Levels

Hepatic drug transporters, old and new: Pharmacogenomics, drug response, and clinical relevance

Hepatology ◽  
2009 ◽  
Vol 50 (4) ◽  
pp. 1014-1016 ◽  
Author(s):  
Marianne K. DeGorter ◽  
Richard B. Kim
Keyword(s):  
Clinical Relevance ◽  
Drug Response ◽  
Drug Transporters ◽  
Hepatic Drug

scholarly journals Imaging of hepatic drug transporters with [131I]6-β-iodomethyl-19-norcholesterol

2019 ◽  
Vol 9 (1) ◽  
Author(s):  
Masato Kobayashi ◽  
Kodai Nishi ◽  
Asuka Mizutani ◽  
Tsuzumi Hokama ◽  
Miki Matsue ◽  
...  
Keyword(s):  
Multidrug Resistance ◽  
Human Liver ◽  
Drug Transporters ◽  
Organic Anion ◽  
Hek293 Cells ◽  
Emission Computed Tomography ◽  
Cancer Resistance ◽  
Mouse Blood ◽  
Hepatic Drug ◽  
Resistance Protein

Abstract We examined whether [131I]6-β-iodomethyl-19-norcholesterol (NP-59), a cholesterol analog, can be used to measure function of hepatic drug transporters. Hepatic uptake of NP-59 with and without rifampicin was evaluated using HEK293 cells expressing solute carrier transporters. The stability of NP-59 was evaluated using mouse blood, bile, and liver, and human liver S9. Adenosine triphosphate-binding cassette (ABC) transporters for bile excretion were examined using hepatic ABC transporter vesicles expressing multidrug resistance protein 1, multidrug resistance-associated protein (MRP)1-4, breast cancer resistance protein (BCRP), or bile salt export pump with and without MK-571 and Ko143. Single photon emission computed tomography (SPECT) was performed in normal mice injected with NP-59 in the presence or absence of Ko143. Uptake of NP-59 into HEK293 cells expressing organic anion transporting polypeptide (OATP)1B1 and OATP1B3 was significantly higher than that into mock cells and was inhibited by rifampicin. NP-59 was minimally metabolized in mouse blood, bile, and liver, and human liver S9 after 120 min of incubation. In vesicles, NP-59 was transported by MRP1 and BCRP. Excretion of NP-59 into bile via BCRP was observed in normal mice with and without Ko143 in the biological distribution and SPECT imaging. NP-59 can be used to visualize and measure the hepatic function of OATP1B1, OATP1B3, and BCRP.

Sign in / Sign up

Export Citation Format

Share Document